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Novel Technologies for in Vivo Imaging
This program announcement (PA) must be read in
conjunction with the current Omnibus Solicitation
of the NIH, Centers for Disease Control and
Prevention, and Food and Drug Administration for
Small Business Innovation Research (SBIR) and
Small Business Technology Transfer (STTR) grant
applications. The solicitation (http://grants.
nih.gov/grants/funding/sbirsttr1/index.pdf or
http://grants.nih.gov/grants/funding/sbirsttr1/
index.doc) contains information about the SBIR and
STTR programs, regulations governing the programs,
and instructional information for submission. All of
the instructions within the current SBIR/STTR
Omnibus Solicitation apply.
The NIEHS, the National Cancer Institute
(NCI), the National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK), and the
National Institute of Neurological Disorders and
Stroke (NINDS) invite applications for the develop-
ment and delivery of novel in vivo image acquisition or
enhancement technologies, methods for biomedical
imaging, and image-guided interventions and therapy.
Applications may incorporate limited pilot or clinical
feasibility evaluations using either preclinical models or
clinical studies. This initiative is primarily intended to
facilitate the proof-of-feasibility, development, and
delivery of novel imaging technologies for early detec-
tion, screening, diagnosis, image-guided interventions,
and treatments of various diseases, and, secondarily, to
facilitate limited evaluation studies to show proof of
concept and functionality.
The interests of the NIEHS focus on detection
of intracellular events including gene expression and
signal transduction pathway alterations, and screen-
ing or diagnosis of tissue and organ toxicities related
to exposures to environmental agents. These areas of
interest include initiation of toxicity or exacerbation
of disease or dysfunction resulting from toxic expo-
sure, treatment, and recovery. The interests of the
NCI focus on imaging in vivo for cancer precondi-
tions, cancer screening, diagnosis, progression, treat-
ment monitoring, recurrence, and image-based
surrogate end points. The NCI’s interests include
development and delivery of imaging technologies
that are cancer-speciﬁc, and optimization and valida-
tion of imaging technologies for cancer applications.
The scope includes system integration, contrast
agents, pre- and postprocessing algorithms and soft-
ware for imaging, image understanding, and related
informatics that are cancer-speciﬁc. The interests of
the NIDDK focus on diabetes mellitus and digestive
and kidney diseases. The interests of the NINDS
focus on development and delivery of neuroimaging
technologies that can be applied to diagnosis and
treatment of neurological disorders.  
This PA is directed toward the development,
optimization, and delivery of innovative image acqui-
sition and enhancement methods, including high-
risk/high-gain research on technologies such as 1)
novel single- and multimodality molecular imaging
systems, methods, agents, and related software and
informatics, including the integration of these tech-
nologies with emerging biomedical imaging methods
for more effective health care delivery for cancer and
other diseases; and 2) novel single- and multimodality
anatomical and functional imaging systems, methods,
agents, and related software and informatics for more
effective health care delivery for cancer and other dis-
eases. In addition, research partnerships among inves-
tigators in both academia and device and drug
industries are encouraged to more rapidly translate
and deliver completed imaging system developments.
This PA will utilize the SBIR/STTR mechanisms
but will be run in parallel with an NCI PA of nearly
identical scope, PA-04-095 (http://grants.nih.gov/
grants/guide/pa-files/PA-04-095.html), that utilizes
the phased innovation award (R21/33) and the
R33 mechanisms for exploratory and developmen-
tal studies, and which is open to a broad range of
organizations. Fast-track applications are encour-
aged in this solicitation because they benefit from
expedited evaluation of progress following phase I
exploratory/feasibility work for immediate decision
on transition to phase II funding for expanded
developmental work.
The overarching research objectives of this PA
are to stimulate development, optimization, and
delivery of novel imaging technologies and methods
to capture, process, validate, present, interpret, or
understand in vivo imaging data that support the
missions of one or more of the institutes involved.
Significant advances in medical imaging tech-
nologies have been made over the past 25 years in
such areas as magnetic resonance imaging (MRI),
computed tomography (CT), nuclear medicine, ultra-
sound, and optical imaging. These advances largely
focused on structural or anatomical imaging at the
organ or tissue level. Now there is an opportunity to
stimulate the development and integration of novel
imaging technologies that exploit our current knowl-
edge of the genetic and molecular bases of various dis-
eases. Molecular biological discoveries have great
implications for prevention, detection, and targeted
therapy. Imaging technologies that can provide similar
kinds of cellular and molecular information (that is,
in vivo molecular imaging) to those currently available
from histological or microarray techniques used for in
vitro studies would be very useful.
The advances in molecular methods pose new
requirements for the performance of conventional
biomedical imaging systems. For example, molecular
imaging systems may need to be optimized for a mol-
ecular probe (or probes) as well as for anatomical
imaging. The integration of molecular imaging meth-
ods into multimodality systems will affect data acqui-
sition, processing, reduction, display, and archiving.
Therefore, there is a need to support advances in
methods for both molecular and conventional
anatomical and functional imaging.
The need to encourage and support biomedical
imaging and imaging technology development by aca-
demic and industrial researchers includes 1) promot-
ing the development of novel high-risk/high-gain
technologies; 2) supporting these technologies to mat-
uration, dissemination, and full exploitation; 3) inte-
grating new technologies into commercially available
imaging systems for targeted applications; 4) harmo-
nizing imaging methods across versions of a single
platform or across multiple platforms to permit the
image-based surrogate outcome metrics of the kind
required for multisite preclinical and clinical investiga-
tions; 5) funding a small number of copies of inte-
grated system prototypes for placement, as required,
for off-site research and clinical feasibility studies; and
6) improving technology transfer, delivery, and dis-
semination by promoting early-stage partnerships
between academia and industry to encourage sharing
of research resources, including data sharing and vali-
dation studies necessary to meet federal regulatory
requirements. Therefore, the aims of this initiative
and the support mechanism are also directed at
encouraging the development and delivery of imaging
tools to support biomedical imaging in general for
applications in oncology and other diseases.
Development of novel imaging technologies
usually requires multidisciplinary approaches and
teams with broad expertise in a variety of research
areas. Such varied expertise might include imaging
physics, chemistry, molecular and cellular biology,
signal and image processing, computer vision, infor-
matics and biostatistics, and clinical sciences. The
coordination and collaboration of investigators with
the necessary variety of disciplines to demonstrate the
utility and applicability of new imaging methods is
encouraged.
The purpose of this initiative is to facilitate the
development of novel imaging technologies for risk
assessment, early detection, screening, diagnosis, or
image-guided treatment of cancer and other diseases
and to facilitate clinical evaluation and optimization
studies that are specifically limited to proof-of-con-
cept and pilot data on clinical functionality of the
development. Clinical trials for clinical validation of
emerging imaging technologies are beyond the scope
of and not responsive to this PA.
Studies with preclinical models and clinical stud-
ies to demonstrate the feasibility of developments are
encouraged, including multisite evaluations, where
appropriate. Methods that establish “ground truth”
are required at appropriate levels of resolution to vali-
date these emerging imaging methods, such as imag-
ing excised tissue using protocols similar to those
used in vivo, or correlation of molecular imaging
results with microarray library analyses. Develop-
ments of molecular probes or targeted contrast
agents are considered important approaches to detec-
tion of molecular changes in vivo to take better
advantage of many technologies with potential for
molecular imaging. The following topics would
make appropriate proposed projects. This list is not
meant to be all-inclusive.
1) Early disease detection. Developments may
address innovative high-resolution imaging methods,
with a particular intent to identify and characterize
abnormalities or other early changes, including mole-
cular events on the path to disease. Novel solutions
for in vivo microscopic imaging systems or micro-
scopic implanted devices with high spatial and/or
temporal resolution that may use either intrinsic or
exogenous contrast agents.
2) Disease screening. These methods may include,
but are not limited to, development and optimiza-
tion of efﬁcient imaging systems for screening, with
the intent of achieving improved sensitivity and
specificity for disease detection. Applications could
address innovative improvements to current imag-
ing methods, including hardware and/or software
upgrades, or emerging imaging sensors and meth-
ods. Research topics of interest include means to
significantly reduce imaging time or effects of
motion, use of novel contrast agents or imaging
probes, and use of technologies that reduce or do
not involve the use of ionizing radiation or contrast
agents and imaging probes. System integration and
software methods could include a variety of image
processing and data reduction techniques including
temporal analysis of serial studies, close-to-real-time
image processing, novel image display methods, and
related imaging informatics for more cost-effective
solutions for screening.
3) Imaging for diagnosis, staging, or monitoring
the effects of therapy. This initiative encourages, but
is not limited to, the development of novel imaging
methods such as functional or molecular imaging or
spectroscopy methods that would significantly
improve the specificity of diagnosis of cancer and
other diseases, allow deterministic methods or
patient-specific staging, or measure early effects of
therapy. Examples of system integration would
include multimodality imaging, image fusion or
registration of the different modalities employed,
development of software methods that would esti-
mate the probability of malignancy or other speciﬁc
disease identification, quantitative information for
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time image analysis.
4) Image-guided biopsy (IGB), image-guided ther-
apy (IGT), and image-guided interventional (IGI) pro-
cedures. This initiative encourages novel approaches
using imaging technologies needed to significantly
improve speciﬁcity, identify lesion extent and micro-
scopic involvement, and minimize tissue damage
accompanying biopsy and therapy. Of particular
interest are innovative approaches to IGB, IGT, or
ITI methods that include novel imaging systems that
provide molecular target information or information
at the cellular or molecular level sufﬁcient for image
guidance and treatment. Examples of system integra-
tion that are of interest include, but are not limited
to, multimodality imaging, navigational systems,
registration methods, real-time feedback mechanisms
for controlling therapy (including radiation therapy),
computer-assisted surgery, or the use of methods
that are adaptive or allow patient-specific optimiza-
tion of treatment.
5) Copies of prototype imaging systems. Support
may be requested to make one or more copies of the
prototype for placement in collaborating facilities for
research purposes, namely preclinical or clinical feasi-
bility investigations, including harmonization across
versions of a single platform or across multiple plat-
forms to enable multicenter comparison studies.
There is the possibility for collaboration with NCI-
funded centers such as the NCI Network for
Translational Research in Optical Imaging or the
Lung Image Database Consortium. 
6) Research resources. Development of publicly
accessible research resources that facilitate a consensus
process for optimization and validation of emerging
imaging technologies is encouraged. Examples
include the development of open source software,
image processing software, and related informatics
that can be ported onto different platforms, methods
and image databases required for validation of soft-
ware performance, and other hardware or informatics
methods that assist in more efﬁcient delivery of imag-
ing technologies for screening, diagnosis, and treat-
ment for cancer and other diseases. 
The SBIR/STTR Omnibus Solicitation indicates
the statutory guidelines on levels of funding support
and periods of project duration for SBIR and STTR
phase I and phase II awards. For this PA, budgets up
to $1 million total costs per year and time periods up
to 3 years for phase II competing continuations for
NCI and NINDS grantees may be requested. For
phase I/phase II fast-track applications, the total dura-
tion of support cannot exceed 5 years.
Applications submitted in response to this PA
will be accepted by 1 August 2004, 1 December
2004, or 1 April 2005. More information on this PA
is available online at http://grants1.nih.gov/grants/
guide/pa-files/PA-04-094.html. The PHS 398
research grant application must be used for all
SBIR/STTR phase I, phase II, and fast-track applica-
tions (new and revised). 
Effective 1 October 2003, applications must
have a Dun and Bradstreet (D&B) Data Universal
Numbering System (DUNS) number as the universal
identiﬁer when applying for federal grants or cooper-
ative agreements. The DUNS number can be
obtained by calling 1-866-705-5711 or through the
D&B website at http://www.dunandbradstreet.com/.
The DUNS number should be entered on line 11 of
the face page of the PHS 398 form. The PHS 398 is
available at http://grants.nih.gov/grants/funding/
phs398/phs398.html. Prepare your application in
accordance with the SBIR/STTR Omnibus
Solicitation and PHS 398. Helpful information for
advice and preparation of the application can be
obtained at http://grants.nih.gov/grants/funding/
sbirgrantsmanship.pdf.
Contact: Guoying Liu, Keyvan Farahani,
Houston Baker, or James A. Deye, NCI, 6130
Executive Plz, Ste 6000, Bethesda, MD 20892-7412
USA, 301-496-9531 for GL, KF, or HB; 301-496-
6111 for JAD, fax: 301-480-3507, e-mail: guoyingl@
mail.nih.gov, farahank@mail.nih.gov, bakerhou@
mail.nih.gov, deyej@mail.nih.gov; Jerrold J. Heindel,
Organs and Systems Toxicology Branch, Division of
Extramural Research and Training, NIEHS, PO
Box 12233, Research Triangle Park, NC 27709
USA, 919-541-0781, fax: 919-541-5064, e-mail: 
heindelj@niehs.nih.gov; Daofen Chen, NINDS,
6001 Executive Blvd, Bethesda, MD 20892-9523
USA, 301-496-1917, fax: 301-402-1501, e-mail:
daofen.chen@nih.gov; or Sanford A. Garfield,
NIDDK, 6707 Democracy Blvd, Rm 685, Bethesda,
MD 20892-5450 USA, 301-594-8803, fax: 301-
420-6271, e-mail: garfields@ep.niddk.nih.gov.
Reference: PA No. PAR-04-094
Epidemiology and Other Health Studies Financial
Assistance Program
The Department of Energy (DOE) Office of
Environment, Safety, and Health announces the
availability of funds to provide medical evaluations in
order to identify occupationally related health
impacts in former DOE workers. This request for
applications (RFA) is a follow-up announcement to a
more general annual notice of potential availability of
grants and cooperative agreements for epidemiologic
and other health studies published in the Federal
Register (60 FR 50561) on 29 September 1995. 
The DOE is seeking applications for a coopera-
tive agreement to fund a medical evaluation program
that will serve all former DOE workers nationwide
and will incorporate activities currently performed
under the Former Worker Medical Screening
Program and the Former Beryllium Worker Medical
Surveillance Program. It is anticipated that a single
award will be made to fund all of these activities.
The Former Worker Medical Screening Prog-
ram was initiated in 1996 to provide targeted medical
screening to former workers subject to health risks as
a result of their employment at the DOE’s defense
nuclear facilities. Since its inception, medical evalua-
tion based on worker exposure has been offered to
former workers through 15 projects at 12 DOE sites.
To date, more than 215,000 former workers have
been invited to participate, approximately 35,000
have indicated interest in participating, and approxi-
mately 25,000 have been screened. Information col-
lected is being used both to improve safety and health
practices for current and future DOE workers and to
assist the DOE in its administration of subtitle D of
the Energy Employees Occupational Illness
Compensation Program Act. 
Another component of the program funded
through this cooperative agreement will be the activi-
ties previously conducted by the DOE’s Former
Beryllium Worker Medical Surveillance Program,
which offers medical testing for beryllium sensitivity
and chronic beryllium disease (CBD) to former
employees who were potentially exposed to beryllium
as a result of their work at various DOE sites not ini-
tially covered by the Former Worker Medical
Screening Program. To date, more than 75,000 for-
mer beryllium workers have been invited to partici-
pate, approximately 25,000 have indicated interest in
participating, and approximately 21,000 program
participants have been screened. 
The DOE intends to award one cooperative
agreement with a number of specific goals, which
include 1) development of efﬁcient methods for con-
tacting and informing former DOE workers about the
provisions of this program; 2) establishment of an
effective communication system (including, for exam-
ple, a toll-free number, a webpage, and other
resources) that former workers may use to contact the
program to ask questions and/or arrange for medical
evaluation related to their DOE work, and that will
serve as a resource and referral service to specialty
physicians when appropriate; 3) provision of a one-
time medical evaluation following medical protocol
and based on a participant’s personal work history (in
some cases, a literature review of the exposures poten-
tially associated with speciﬁc sites may be useful)—in
order to maximize the usefulness of these examina-
tions in detecting conditions with latency periods, the
program should focus on potential participants who
separated from the DOE before 1998, and sympto-
matic individuals should enroll as soon as possible;
4) communication of information to former work-
ers regarding the nature of their health risks and
recommendations for follow-up, based on test results;
5) provision of a follow-up beryllium sensitization
blood test for a symptomatic individual upon request
or to an otherwise concerned individual at no greater
frequency than once every three years; 6) use of local
physicians (especially the participants’ personal physi-
cians, when available) to provide these medical evalua-
tions—orientation and education of local physicians
regarding the use of the program’s medical protocol
will be provided as necessary; 7) use of physicians and
other health care professionals who are appropriately
licensed in the state(s) in which they practice and
maintain adequate professional liability insurance; 8)
provision of logistical assistance and reimbursement of
travel costs to the small number of participants who
may have to travel more than 150 miles each way to
receive their evaluation (speciﬁc details will be decided
in conjunction with the DOE program manager); 9)
distribution of a DOE-provided ﬂyer with informa-
tion on various worker compensation alternatives; 10)
establishment of quality assurance measures to ensure
that program services are delivered according to
protocol and verify that all laboratories and radiology
facilities used are appropriately certiﬁed; 11) submis-
sion of detailed monthly financial and quarterly
progress reports to the DOE (reporting format and
content to be speciﬁed) and participation in periodic
meetings (approximately one per year) and monthly
conference calls with the DOE regarding project sta-
tus; 12) compliance with the Health Insurance
Portability and Accountability Act of 1996 and all
relevant portions of the Privacy Act; 13) compliance
with DOE data disposition requirements upon pro-
ject completion; and 14) evaluation of former work-
ers’ satisfaction with the project medical services using
an acceptable patient satisfaction survey such as those
developed for the Johns Hopkins Health Center or
the Mayo Clinic.
Subject to ﬁscal year 2005 congressional appro-
priations, the maximum amount for a single award
made under this announcement is expected to be
$6 million per year or $30 million total, and the
minimum amount for a single award is expected to
be $4 million per year or $20 million total. The
actual level of funding will be based on the applica-
tion selected and the appropriations received.
Applications must be prepared using the SF 424
form. The SF 424 form is available at http://
professionals.pr.doe.gov/ma5/ma-5web.nsf/
FinancialAssistance/IIPSFAForms?OpenDocument.
Applications must be received by 30 June 2004. 
Contact: Ron Barnes, 301-903-1244, e-mail:
ron.barnes@eh.doe.gov. Reference: DE-PS02-
04EH04022
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